Registration Strip Icon for discussion Register to chat with like-minded investors on our interactive forums.

Kronos Bio (KRON)

Kronos Bio Inc
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:KRON
DateTimeSourceHeadlineSymbolCompany
27/11/202414:25AllPennyStocks.comCalifornia Biotech Stock Bid Up Prior To Opening Bell On Major AnnouncementNASDAQ:KRONKronos Bio Inc
27/11/202412:30GlobeNewswire Inc.Kronos Bio Announces CEO Transition and Reduction in ForceNASDAQ:KRONKronos Bio Inc
15/11/202405:15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:KRONKronos Bio Inc
14/11/202421:02GlobeNewswire Inc.Kronos Bio Highlights Preclinical Data that Show p300 KAT Inhibitors Reduce Inflammation in an Oral Presentation at ACR Convergence 2024NASDAQ:KRONKronos Bio Inc
13/11/202421:06Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:KRONKronos Bio Inc
13/11/202421:05GlobeNewswire Inc.Kronos Bio Reports Third Quarter 2024 Financial Results and Corporate Update Including Plan to Evaluate Strategic AlternativesNASDAQ:KRONKronos Bio Inc
07/11/202421:47Edgar (US Regulatory)Form S-3 - Registration statement under Securities Act of 1933NASDAQ:KRONKronos Bio Inc
05/11/202414:00GlobeNewswire Inc.Kronos Bio to Present Data at the ASH Annual Meeting from p300 KAT Inhibition Program in Multiple MyelomaNASDAQ:KRONKronos Bio Inc
23/10/202412:55GlobeNewswire Inc.Kronos Bio Data Presentation at EORTC-NCI-AACR Symposium Highlights the Importance of p300 KAT Inhibition in HPV-Driven TumorsNASDAQ:KRONKronos Bio Inc
15/10/202422:57Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:KRONKronos Bio Inc
15/10/202422:55Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:KRONKronos Bio Inc
09/10/202412:55GlobeNewswire Inc.Kronos Bio to Present Data at the EORTC-NCI-AACR Symposium that Supports p300 KAT Inhibition in HPV-Driven TumorsNASDAQ:KRONKronos Bio Inc
07/10/202412:55GlobeNewswire Inc.Kronos Bio Announces Selection of Autoimmune Development Candidate for Sjögren’s DiseaseNASDAQ:KRONKronos Bio Inc
25/09/202412:55GlobeNewswire Inc.Kronos Bio to Present Data at ACR Convergence 2024 to Support p300 KAT Inhibition as an Approach to Anti-Inflammatory TherapyNASDAQ:KRONKronos Bio Inc
23/09/202412:55GlobeNewswire Inc.Kronos Bio Highlights Data at AACR Ovarian Cancer Research Symposium that Supports Clinical Evaluation of Istisociclib in Advanced Ovarian CancerNASDAQ:KRONKronos Bio Inc
03/09/202412:55GlobeNewswire Inc.Kronos Bio Announces Participation in Medical and Investor Conferences in SeptemberNASDAQ:KRONKronos Bio Inc
08/08/202420:15GlobeNewswire Inc.Kronos Bio Reports Second Quarter 2024 Financial Results and Pipeline UpdateNASDAQ:KRONKronos Bio Inc
08/08/202420:03Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:KRONKronos Bio Inc
23/07/202420:15GlobeNewswire Inc.Kronos Bio Announces First Patient Dosed with KB-0742 in an Expansion Cohort Focused on Platinum-Resistant High-Grade Serous Ovarian CancerNASDAQ:KRONKronos Bio Inc
04/06/202421:02Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:KRONKronos Bio Inc
04/06/202420:58Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:KRONKronos Bio Inc
23/05/202421:15GlobeNewswire Inc.Kronos Bio to Present Clinical Update on Phase 1/2 Trial of KB-0742 at the 2024 American Society of Clinical Oncology (ASCO) Annual MeetingNASDAQ:KRONKronos Bio Inc
22/05/202420:30GlobeNewswire Inc.Kronos Bio to Participate in Three Upcoming Healthcare Conferences and EventsNASDAQ:KRONKronos Bio Inc
21/05/202420:15Edgar (US Regulatory)Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) materialNASDAQ:KRONKronos Bio Inc
21/05/202412:20Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:KRONKronos Bio Inc
21/05/202412:15GlobeNewswire Inc.Kronos Bio Appoints Deborah Knobelman, Ph.D. as Chief Operating Officer and Chief Financial Officer NASDAQ:KRONKronos Bio Inc
09/05/202420:12Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:KRONKronos Bio Inc
09/05/202420:08Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:KRONKronos Bio Inc
09/05/202420:05GlobeNewswire Inc.Kronos Bio Reports First-Quarter 2024 Financial ResultsNASDAQ:KRONKronos Bio Inc
24/04/202420:01GlobeNewswire Inc.Kronos Bio to Present Clinical Update on Phase 1/2 Trial of KB-0742 at the 2024 American Society of Clinical Oncology (ASCO) Annual MeetingNASDAQ:KRONKronos Bio Inc
 Showing the most relevant articles for your search:NASDAQ:KRON

Your Recent History

Delayed Upgrade Clock